Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: INBX

Inhibrx Biosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for INBX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-9.04

Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 06:50 UTC.

What Inhibrx Biosciences, Inc. does

Inhibrx is a clinical-stage biopharmaceutical company that develops novel biologic therapeutic candidates using proprietary modular protein engineering platforms. Following a spin-off from its former parent company and a concurrent transaction with Sanofi in May 2024, the company now operates independently with a focused pipeline of two clinical-stage programs: ozekibart, a tetravalent DR5 agonist being investigated in solid tumors including chondrosarcoma and colorectal cancer, and INBRX-106, a hexavalent OX40 agonist being studied in non-small cell lung cancer and head and neck squamous cell…

Summarized from Inhibrx Biosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-9.04

Revenue, margins & earnings

FY2023: net loss $241M on revenue $2M$2MFY2023FY2024 Revenue: $200,000 — margin split not shown (non-operating gains)FY2024: net income $1.69B exceeded revenue $200,000 by $1.69B — non-operating gains (e.g. asset sales), not operating profit$200,000FY2024FY2025: net loss $140M on revenue $1M$1MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-14
  • 2026-10-14Chief Executive OfficerPurchase100$8.6K
  • 2026-10-14Chief Executive OfficerPurchase2,470$207.7K
  • 2026-10-14Chief Executive OfficerPurchase2,451$208.3K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Inhibrx Biosciences, Inc. do?

Inhibrx is a clinical-stage biopharmaceutical company that develops novel biologic therapeutic candidates using proprietary modular protein engineering platforms.

When did INBX last file with the SEC?

Inhibrx Biosciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 06:50 UTC. This page is also available as JSON at /api/data?ticker=INBX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for INBX and 5,000+ tickers.

Create a free account — keep INBX
For your agent
GET /api/data?ticker=INBX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt